Clinical trials: sponsored by Boehringer Ingelheim
Parkinson Disease, Depression
Profile of Depressive Symptoms in Parkinsons Disease
To explore or establish the relationship between cognitive, mood and motor symptoms in PD to scores on depression rating scales in a naturalistic setting.
- Trial name
- NCT00349310
- Testing
- Pramipexole
- Where
- 24 sites in Austria, France and 6 more
- Volunteers
- 1,018 people
- Sponsor
- Boehringer Ingelheim
Hypertension, Diabetic Nephropathies
A Prospective, Randomised, Double-blind, Double-dummy, Forced-titration, Multicentre, Parallel Group, One Year Treatment Trial to Compare Telmisartan (MICARDIS) 80 mg Versus Losartan (COZAAR) 100 mg, in Hypertensive Type 2 Diabetic Patients With Overt Nephropathy (AMADEO Study)
A number of blood pressure lowering drugs in the class known as angiotensin receptor blockers (ARB) have been shown to slow the decline in kidney function of patients with type 2 diabetes, high blood pressure, and kidney disease.
- Trial name
- NCT00168857
- Testing
- telmisartan, losartan
- Where
- 109 sites in United States, Argentina and 8 more
- Volunteers
- 860 people
- Sponsor
- Boehringer Ingelheim
Hypertension, Metabolic Syndrome X
Phase IV, 9 Weeks Comparison Between MICARDIS 80 mg and Amlodipine 10 mg on Biological PPAR Gamma Activities
The objective of the study is to compare PPAR activities (increase of adiponectin level) between MICARDIS and amlodipine after 6 weeks of treatment in hypertensive patients with metabolic syndrome.
- Trial name
- NCT00242814
- Testing
- Micardis, Amlodipine, Abdominal biopsy
- Where
- 31 sites in France
- Volunteers
- 100 people
- Sponsor
- Boehringer Ingelheim
Healthy
Safety, Tolerability and Pharmacokinetics of Single Rising and Multiple Oral Doses of Telmisartan / Hydrochlorothiazide (HCTZ) in Healthy Male Volunteers
Group 1: To investigate safety, tolerability and pharmacokinetics of Telmisartan + HCTZ (T40/H12.5 and T80/H12.5) Group 2: To investigate safety, tolerability and pharmacokinetics of Telmisartan + HCTZ (T80/H12.5 x 7 days)
- Trial name
- NCT02262780
- Testing
- Low dose of telmisartan, High dose of telmisartan, HCTZ
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
General Practice Quality Assurance Project. Chronic Obstructive Pulmonary Disease (COPD) Diagnosis and Treatment
A Cross sectional observational Quality Assurance Project in General Practice to COPD Diagnosis and Treatment
- Trial name
- NCT00319813
- Testing
- Education
- Volunteers
- 8,000 people
- Sponsor
- Boehringer Ingelheim
Hypertension
PROBE Investigation of the Safety & Efficacy of Telmisartan (Micardis®) vs Ramipril (Altace®) Using ABPM in HTN
Demonstrate that telmisartan 80mg was at least as effective and possibly superior to ramipril 5mg \& 10mg in lowering mean ambulatory DBP and SBP during the last 6 hrs of the 24-hr dosing interval in mild-to-moderate…
- Trial name
- NCT00274599
- Testing
- Telmisartan, Ramipril
- Where
- 74 sites in United States, Canada
- Volunteers
- 812 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
12 Week Efficacy of Tiotropium Versus Placebo in Patients With Mild COPD According to Swedish Guidelines (SPIRIMILD)
To show that treatment with tiotropium inhalation capsules (18 μg q.d.) via HandiHaler® improves lung function in patients with mild COPD according to Swedish guidelines.
- Trial name
- NCT00144196
- Testing
- tiotropium (Spiriva)
- Where
- 27 sites in Sweden
- Volunteers
- 224 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Trial Comparing Treatment With Tiotropium Inhalation Capsules to Combivent® Inhalation Aerosol in COPD Patients.
The objective of this study is to evaluate the efficacy and safety of 12 weeks treatment with tiotro pium HandiHaler® 18 mcg daily compared to Combivent® MDI CFC Inhalation Aerosol 2 actuations qid in COPD patients currently…
- Trial name
- NCT00388882
- Testing
- tiotropium, ipratropium bromide / albuterol
- Where
- 40 sites in United States, Argentina and 3 more
- Volunteers
- 327 people
- Sponsor
- Boehringer Ingelheim
HIV Infections, Hepatic Insufficiency
A Pharmacokinetic Study to Assess Nevirapine [Viramune] Levels in HIV Infected Patients With Impaired Hepatic Functions
The objective of this study was to evaluate the steady-state clearance of nevirapine among HIV-1 positive patients with hepatic fibrosis, and to examine whether the degree of hepatic impairment influences clearance.
- Trial name
- NCT00144248
- Testing
- nevirapine
- Where
- 8 sites in United States, France and 1 more
- Volunteers
- 51 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
DIA_CENTRAL:T2D Treatment Pattern in Central Europe
This is a non-interventional study using existing data including medical chart review.
- Trial name
- NCT03807440
- Testing
- Empagliflozin, Sodium Glucose Transporter 2 inhibitor, Dipeptidyl-peptidase 4 inhibitor
- Where
- 177 sites in Bulgaria, Czechia and 3 more
- Volunteers
- 4,083 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Pharmacokinetics and Safety Comparison of Tiotropium Inhalation Powder Administered as the Bromide Salt From Hard Polyethylene Capsule Via the HandiHaler® 2 and Spiriva® HandiHaler® in Patients With Chronic Obstructive Pulmonary Disease (COPD)
The primary objective of this trial was to establish non-inferiority of lung function response to tiotropium 10 μg, formulated as inhalation powder in the polyethylene hard capsule and delivered via the HandiHaler® 2, compared to…
- Trial name
- NCT02242266
- Testing
- Tiotropium low dose, Tiotropium medium dose, Spiriva® HandiHaler® high dose
- Volunteers
- 121 people
- Sponsor
- Boehringer Ingelheim
HIV Infections
Dual Boosted - Protease Inhibitor (PI) Pharmacokinetics (PK) Trial (Tipranavir / Ritonavir) in Highly Treatment-experienced HIV-1 Infected Patients
This is an open-label, randomized, parallel group pharmacokinetics trial of tipranavir/ritonavir (TPV/RTV), alone or in combination with RTV-boosted saquinavir (SQV), amprenavir (APV) or lopinavir (LPV), plus an optimized…
- Trial name
- NCT00056641
- Testing
- tipranavir, ritonavir, saquinavir
- Where
- 109 sites in United States, Australia and 11 more
- Volunteers
- 328 people
- Sponsor
- Boehringer Ingelheim
HIV Infections
3 TPV/RTV Doses in Multiple ARV Experienced Patients - Tipranavir Dose Defining Study
A dose defining study of the protease inhibitor tipranavir (TPV), boosted with low dose ritonavir (RTV). Three dose combinations of TPV/RTV are administered to multiple antiretroviral experienced patients and the dose that…
- Trial name
- NCT00275444
- Testing
- Tipranavir
- Where
- 62 sites in United States, Australia and 7 more
- Volunteers
- 216 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Effect of Tiotropium (Spiriva) on Exercise Tolerance in COPD Patients
To investigate whether tiotropium (Spiriva) improves exercise endurance in patients with COPD
- Trial name
- NCT00274508
- Testing
- tiotropium bromide
- Where
- 28 sites in United States, Australia and 2 more
- Volunteers
- 261 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
A Multiple Dose Comparison of Tiotropium Inhalation Capsules and Salmeterol Inhalation Aerosol.
The objective of the study was to evaluate the degree of improvement in lung function in patients with chronic obstructive pulmonary disease (COPD) after treatment with tiotropium inhalation capsules compared to salmeterol…
- Trial name
- NCT00274560
- Testing
- Tiotropium, Salmeterol
- Where
- 50 sites in United States, Finland and 6 more
- Volunteers
- 653 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Efficacy and Safety Comparison of Tiotropium Inhalation Solution (Respimat Inhaler) and Spiriva HandiHaler in COPD
Non-inferiority of lung function response to Tiotropium inhalation solution compared to Spiriva HandiHaler
- Trial name
- NCT00239447
- Testing
- Tiotropium, HandiHaler, Respimat SMI
- Where
- 11 sites in United States, Canada
- Volunteers
- 131 people
- Sponsor
- Boehringer Ingelheim
Neoplasms
A Trial to Find the Safe Dose for BI 905681 in Patients With Incurable Tumours or Tumours That Have Spread
The primary objective of this trial is to determine the maximum tolerated dose (MTD)/optimal biological dose (OBD) of BI 905681 given as an intravenous infusion and to determine the recommended dose and dosing schedule for…
- Trial name
- NCT04147247
- Testing
- BI 905681
- Where
- 3 sites in United States
- Volunteers
- 21 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive, Asthma
Flow Rate Effect Respimat Inhaler Versus a Metered Dose Inhaler Using Berodual in Patients With Chronic Obstructive Pulmonary Disease (COPD)
The objective of this trial is to compare the total and regional deposition of aerosol in the lungs and oropharynx of patients with COPD at 3 different inspiratory flow rates following inhalation of Berodual delivered via the…
- Trial name
- NCT00153075
- Testing
- Berodual Respimat, Berodual HFA-MDI
- Where
- Germany
- Volunteers
- 19 people
- Sponsor
- Boehringer Ingelheim
Healthy
A Study to Test How Well Different Doses of BI 765845 Are Tolerated by Healthy People
The main objectives of this trial are to investigate safety, tolerability and pharmacokinetics (PK) of BI 765845 in healthy male subjects and female subjects of non-childbearing potential following intravenous administration of…
- Trial name
- NCT06139315
- Testing
- BI 765845
- Where
- Belgium
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Osteoarthritis
Study to Assess the Efficacy and Safety of Meloxicam vs. Diclofenac SR in Patients With Osteoarthritis of the Knee
To assess the efficacy and safety of meloxicam 7.5mg once daily compared with diclofenac 100mg SR once daily over a treatment period of 8 weeks
- Trial name
- NCT02183129
- Testing
- Diclofenac, Meloxicam
- Volunteers
- 91 people
- Sponsor
- Boehringer Ingelheim
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.